Folfiri as Third Line of Treatment
The aim of this study is to investigate the activity of Folfiri as Third line of treatment in mGC progressed after ramuciramb-based second line.
Gastric Cancer|Ramucirumab|Third Line
response rate (confirmed complete and partial response)., rate of patients with complete or partial response, From date of enrollment to best radiological evaluation, up to 12 months
Progression free survival, Time from start of treatment to Progression or death, From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months|Overall survival, Time from start of treatment to Death for any cause, From date of enrollment until the date of death from any cause, whichever came first, assessed up to 12 months|Toxicity, Incidence of Toxicity according National Cancer Institute Common Terminology Criteria, From date to start therapy up to 12 months
The aim of this study is to investigate the activity of Folfiri as Third line of treatment in mGC progressed after ramuciramb-based second line.